Clinical application of innovative blue laser-mediated theranostic strategies in the diagnosis, surgery and recurrent prevention of high-risk non-muscle invasive bladder cancer (NMIBC): a multicenter randomized controlled clinical trial

INTERVENTION: group 1:White light cystoscopy + TURBT;group 2:preoperative PDD + blue laser en bloc resection + postoperative PDT; CONDITION: Bladder cancer PRIMARY OUTCOME: Tumor recurrence rate at 1 year after surgery; INCLUSION CRITERIA: 1. All cystoscopic examination and imaging data are determined to be non‐muscle invasive bladder cancer (NMIBC), which requires transurethral surgery (non‐diagnostic purpose), and is determined to be high‐risk NMIBC according to the risk of recurrence and progression (meet any of the following: ?T1 tumor; ?G3 or high‐grade urothelial carcinoma; ?CIS; ?Meet at the same time: multiple, recurrent, and TaG1‐2 or low‐grade urothelial carcinoma with a diameter > 3 cm); 2. Age between 18 and 80 years old; 3. ECOG score 0‐1; 4. Women of childbearing age should have a negative urine pregnancy test; 5. Take reliable contraceptive measures during the study; 6. The patient voluntarily participated and signed the informed consent.